The Parenteral Drug Delivery Market

Pii is proud to offer its second Aseptic e-book with exclusive insight into the significant trends impacting the aseptic industry.

This follow-up report focuses on:

• Key parenteral areas of aseptic manufacturing
• Scale-up
• Primary packaging options
• Targeted treatments

Parenteral drugs are now accounting for almost half of all approved new molecular entities, due in large part to the role they play in treating chronic diseases as well as a rise in self-administration.

But there are significantly high standards that must be met to ensure the strength of the active ingredients, purity, and quality of the final products. For this reason, bio/pharmaceutical companies are seeking the experience and knowledge of contract development and manufacturing organizations (CDMOs).

In fact, contract fill-and-finish services are one of the most commonly outsourced services presently. Partnering with a CDMO that has the agility to handle both small and large molecules and offers highly specialized capabilities like prefilled syringes, lyophilization, and cartridges will ensure your outsourcing project is cost effective and successful.